StreetInsider.com News Articles

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:30:00 -0400

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.

The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:30:00 -0400

The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal

Form 6-K Nasus Pharma Ltd For: Sep 04

Fri, 04 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260904/27029906.html

Form F-3 Nasus Pharma Ltd

Tue, 01 Sep 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260901/27013577.html

Form EFFECT Nasus Pharma Ltd

Fri, 21 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958186.html

Form EFFECT Nasus Pharma Ltd

Fri, 21 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26958186.html

Form 6-K Nasus Pharma Ltd For: Aug 19

Wed, 19 Aug 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26948138.html

Form 6-K Nasus Pharma Ltd For: Aug 19

Wed, 19 Aug 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260819/26948138.html

Nasus Pharma CFO departs, interim replacement named

Wed, 19 Aug 2026 07:00:23 -0400

Nasus Pharma Ltd. (NYSE American: NSRX) announced that Chief Financial Officer Eyal Rubin is leaving the company to pursue an opportunity outside the life sciences industry. Rubin's last day is set for September 18, 2026.

Oren Elmaliach, the company's Director of Finance, has been appointed Interim Chief Financial Officer. Elmaliach has been with Nasus Pharma since its founding and holds a certified public accountant designation with more than 15 years of financial experience, including work with public and private life sciences companies and within U.S. public markets and financial reporting.

"While I am disappointed that Eyal will be leaving Nasus, I am

Nasus Pharma CFO departs, interim replacement named

Wed, 19 Aug 2026 07:00:23 -0400

"While I am disappointed that Eyal will be leaving Nasus, I am

Nasus Pharma Announces Transition of Chief Financial Officer

Wed, 19 Aug 2026 07:00:00 -0400

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer.

Nasus Pharma Announces Transition of Chief Financial Officer

Wed, 19 Aug 2026 07:00:00 -0400

Nasus Pharma Announces Transition of Chief Financial Officer

Wed, 19 Aug 2026 07:00:00 -0400

Nasus Pharma Announces Transition of Chief Financial Officer

Wed, 19 Aug 2026 07:00:00 -0400

Form POS AM Nasus Pharma Ltd

Wed, 19 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26946602.html

Form POS AM Nasus Pharma Ltd

Wed, 19 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26946602.html

Form 6-K Nasus Pharma Ltd For: Jun 30

Mon, 17 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260817/26935449.html

Form 6-K Nasus Pharma Ltd For: Jun 30

Mon, 17 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260817/26935449.html

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Mon, 17 Aug 2026 08:14:00 -0400

Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer